Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
αPD1-MSLN-CAR T cells in advanced solid tumors
NCT05373147Phase 1Unknown
- Sponsor
- Shanghai Mengchao Cancer Hospital
- Start
- Oct 2020
- Primary completion
- Feb 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BZD1901 in solid tumor, sponsored by Shanghai Mengchao Cancer Hospital. Primary endpoint: Dose-limiting toxicity at 28 days. Status: unknown.
02
Drugs
BZD1901
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05373147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05373147.